Novartis places big, broad bet on cancer immunotherapy

June 8 (Reuters) - Novartis is well placed in the hot field of cancer immunotherapy, despite being behind rivals in developing immune system-boosting drugs known as checkpoint inhibitors, a top executive at the Swiss drugmaker said on Monday.